|
|
Imagenetix Commissions New Study to Evaluate Celadrin(R) Capsules for Patients with Knee Osteoarthritis
March 20, 2006
SAN DIEGO--(BUSINESS WIRE)--March 20, 2006--Imagenetix
Inc. (OTCBB: IAGX - News), a company focused on joint health and
joint health-related markets, today announced it has commissioned
a new multi-site study to measure the effectiveness of its Celadrin® oral
capsules for improving overall joint health in patients with osteoarthritis
of the knee.
The primary purpose of this study is to
confirm the positive clinical results, published in 2002 in the internationally
acclaimed peer-reviewed Journal of Rheumatology, demonstrating that
Celadrin® oral capsules improved range of motion and overall
function in knee osteoarthritis patients.
The upcoming 60-day study,
a double-blind, placebo-controlled trial expected to be completed
this summer, will involve 84 patients currently diagnosed with moderate
to severe knee osteoarthritis. The patients will be studied at two
locations, in Northridge, Calif., and Ellicot City, Md., operated
by Medicus Research, a private clinical trials facility.
Dr. Jay
Udani, medical director of Medicus as well as medical director of
Northridge Hospital Integrative Medicine Program and assistant clinical
professor at UCLA School of Medicine, will serve as the study's project
manager and principal investigator.
Celadrin® is an all-natural
proprietary Imagenetix compound that works by supporting the lubrication
of joints and enhancing fluids that cushion bones and joints. Clinical
research published recently in both Journal of Rheumatology and Journal
of Strength & Conditioning Research demonstrated that knee osteoarthritis
patients using topical administration of Celadrin® cream had
significant improvement in knee range of motion, balance, mobility
and overall knee function, without side effects.
"We are firmly
committed to providing the most complete scientific data regarding
the efficacy of our products," said Imagenetix President William
P. Spencer. "We look forward to making this data on Celadrin® available
at the earliest possible opportunity."
Imagenetix Inc. develops,
formulates, private-labels, and produces nutritional supplements,
over-the-counter topical creams, skin care products and pharmaceuticals
for inflammatory-related markets.
|
